Gene Therapy Durability Summit 2023

Memo

Uniting the leading minds in gene therapy at the Gene Therapy Durability Summit, join us to:- Leverage knowledge from current clinical trials with relevant durability data across a range of indication types using AAV- Better understand what can be extrapolated and how to gain confidence in the data collected- Build study designs with durability in mind and explore how well preclinical models have predicted clinical durability to dateHear from the likes of Pfizer, Selecta Biosciences, Spark Therapeutics, Rocket Pharmaceuticals, ASC Therapeutics and more across a preconference workshop day, expert presentations, interactive panel discussions, dedicated Q and A time and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field.Register to attend - https://ter.li/bz9qb6URLs:Brochure: https://go.evvnt.com/1534231-0?pid=5569 Tickets: https://go.evvnt.com/1534231-1?pid=5569   Date and Time: On Tuesday April 25, 2023 at 8:00 am to Thursday April 27, 2023 at 5:00 pmVenue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United StatesPrices:Conference + 2 Workshops: USD 4297.00,Conference + 1 Workshop: USD 3648.00,Conference Only: USD 2599.00Speakers: Annahita Keravala, Chief Scientific Officer, Genascence Corporation, Chris Doering, Chief Scientific Officer, Expression Therapeutics, Christopher Riling, Head of Liver Research, Spark Therapeutics, Dongsheng Duan, Professor, University of Missouri School of Medicine, Jean-Phillippe Combal, Chief Scientific Officer, Vivet Therapeutics, Jeff Boyle, Chief Science Officer, American Gene Technologies International, Jonathan Schwartz, Chief Medical Officer, Rocket Pharmaceuticals, Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences, Kruti Patel, Principal Scientist, Pfizer, Manish Muhuri, Scientist, Biogen, Martin Schulz, Global Senior Director - Medical Gene Therapy Platform, Pfizer, Michael Friedman, Executive Director - Clinical Development, Adverum, Moanaro Biswas, Associate Professor of Pediatrics, Indiana University, Mohammad Shadid, Executive Director and Head Of Nonclinical Development, Aruvant Sciences, Oscar Segurado, Chief Medical Officer, ASC Therapeutics, Pavan Battiprolu, Executive Director and Head Of Translation, Gene Therapy, Poseida Therapeutics, Rahul Kaushik, Group Leader - AAV-Exosome gene therapy, Evox Therapeutics, Roland Kolbeck, Chief Scientific Officer, Spirovant Sciences, Vassili Valayannopoulos, Head of Clinical Development, Decibel Therapeutics